Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
108 participants
OBSERVATIONAL
2023-11-09
2025-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The relationship between the dynamics of urinary microbiota composition and the pathobiology of UTIs is beginning to be studied in humans (Neugent et al., 2020). Price et al. analyzed the urine of women with UTI symptoms using EQUC culture, compared to a symptom-free control group (Price et al., 2016). More precise identification of cultured bacteria revealed the presence of bacteria that were not detected using conventional culture (such as Lactobacillus iners, Gardnerella vaginalis, Prevotella sp., and Aerococcus urinae). In addition, sequencing allowed the characterization of polymicrobial communities, present in many of the samples analyzed.
These findings have led to a significant revision of the traditional perception of UTIs. It has thus been suggested that, following a disruption in the homeostasis of the urinary microbiota (urinary dysbiosis), certain bacteria considered commensals of the urinary tract can become pathogenic and lead to UTIs (Gerges-Knafl et al., 2020).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimization Management Study of Community Urinary Tract Infections Spectrum
NCT03655548
The Urinary Microbiome and Its Relationship to the Urinary and Serum Metabolome in Healthy Peri- and Postmenopausal Women
NCT06573827
Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria
NCT06910878
Selective Reporting for Antibiotic Susceptibility Testing and GPs' Prescribing of Broad-spectrum Antibiotics in Women With E. Coli UTIs
NCT06067386
: Bacterial Infections in Injecting Drug Users
NCT04550767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Furthermore, integrating urinary metabolomics with other "omics" technologies, such as microbiome, offers a more comprehensive view of the complex interactions that occur during an infection.
Existing studies of the urinary microbiome are primarily retrospective, conducted on small patient populations, and with little medical data collected.
This study therefore proposes to prospectively enroll 150 subjects (50 patients with proven UTI and 100 healthy volunteers) to study their bacterial urinary microbiota using EQUC and NGS techniques, compared to standard culture results. In addition, precise medical metadata will be collected prospectively and compared with microbiota data.
The research hypothesis is that the composition of the bacterial urinary microbiota differs between patients with clinically proven UTI and those without UTI.
This study will also test other secondary hypotheses, including:
* That certain bacterial species present in the urine of adult women are not routinely detected using standard culture conditions.
* That certain bacterial species in the urinary microbiota are not cultivable and are detectable only by NGS.
* That patients with clinically proven UTI have a lower diversity and less richness of the bacterial urinary microbiota compared to patients without UTI.
* That host factors are associated with microbial signatures.
* That the urinary metabolome of patients with UTI is different from that of healthy volunteers
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
"with urinary tract infection (UTI)" groups
composition of the urinary microbiota (urotypes) of patients in the "with urinary tract infection (UTI)" groups
No interventions assigned to this group
"healthy volunteer (absence of UI)" groups
composition of the urinary microbiota (urotypes) of healthy volunteers (absence of UI) "
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women
* Between 18 and 45 years old
* Premenopausal
* With biological and clinical criteria for UTI
* Without urinary tract abnormalities
* Having read the information sheet and not objecting to participation
* Patient affiliated with social security
Healthy volunteers:
* Women
* Between 18 and 45 years old
* Premenopausal
* Without biological or clinical criteria for UTI
* Without urinary tract abnormalities
* Having read the information sheet and not objecting to participation
* Person deprived of liberty by an administrative or judicial decision, person placed under judicial protection, guardianship, or curatorship
Exclusion Criteria
* Pregnancy
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sandrine SD DAHYOT, Doctor
Role: PRINCIPAL_INVESTIGATOR
University Rouen Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Microbiologie - Laboratoire de Bactériologie
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N° IDRCB : 2023-A00661-44
Identifier Type: OTHER
Identifier Source: secondary_id
2022/0309/OB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.